Scholarlink

Background <p>Schizophrenia (SCZ) is marked by profound biological and clinical heterogeneity, presenting major challenges for accurate diagnosis and personalized treatment. Traditional classifications based solely on clinical presentation are limited by inter-individual variability, overlapping symptom profiles, and low stability across disease stages and treatment states. Dysregulation of the excitation–inhibition (E–I) balance within neural circuits is thought to underpin diverse positive and negative symptoms. Classification based on neural excitability may therefore provide critical insights into disentangling this heterogeneity.</p> Methods <p>We applied a cortical excitability (CE) mapping approach to spatially characterize E–I dysregulations in 77 drug-naïve first-episode SCZ (FES) patients and 76 healthy controls (HCs). CE abnormalities were identified using voxel-wise comparisons, and patients were subsequently clustered into subtypes based on the spatial patterns of CE alterations. Longitudinal analyses assessed the subgroups’ clinical trajectories over 12&#xa0;months of antipsychotic treatment. Furthermore, CE maps were integrated with transcriptomic and neuroreceptor datasets to analyse potential molecular mechanisms underlying the observed CE abnormalities.</p> Results <p>Relative to HCs, FES patients exhibited CE abnormalities primarily in the bilateral frontal lobes, sensorimotor cortex, and right cuneus. Two subtypes were identified, differing in both the spatial extent of CE abnormalities and their clinical profiles: FES1 showed more widespread CE reductions across frontal and association cortices, associated with greater affective and cognitive burden, whereas FES2 demonstrated a comparatively preserved CE profile and milder symptom expression. Subsequent transcriptomic and receptor analyses revealed distinct biological underpinnings: FES1 was associated with synaptic dysfunction and neurodevelopmental disruption, while FES2 reflected multisystem involvement potentially accompanied by compensatory processes.</p> Conclusions <p>CE-based subtyping captures clinically and biologically meaningful heterogeneity in FES. Moreover, this approach provides a promising framework for bridging neural circuit dysfunction with molecular signatures and may advance precision psychiatry in SCZ.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cortical excitability mapping stratifies neurobiological subtypes of schizophrenia with genetic and molecular signatures

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月25日

查看全文
  • Sixuan Guo,
  • Yu Zhao,
  • Xiao Ji,
  • Xiqin Liu,
  • Luying Li,
  • Yiling Guo,
  • Xinlan Zhang,
  • Ruoxi Xie,
  • Jiaxin Zeng,
  • Hongbiao Sun,
  • Su Lui,
  • Qiyong Gong

摘要

Background

Schizophrenia (SCZ) is marked by profound biological and clinical heterogeneity, presenting major challenges for accurate diagnosis and personalized treatment. Traditional classifications based solely on clinical presentation are limited by inter-individual variability, overlapping symptom profiles, and low stability across disease stages and treatment states. Dysregulation of the excitation–inhibition (E–I) balance within neural circuits is thought to underpin diverse positive and negative symptoms. Classification based on neural excitability may therefore provide critical insights into disentangling this heterogeneity.

Methods

We applied a cortical excitability (CE) mapping approach to spatially characterize E–I dysregulations in 77 drug-naïve first-episode SCZ (FES) patients and 76 healthy controls (HCs). CE abnormalities were identified using voxel-wise comparisons, and patients were subsequently clustered into subtypes based on the spatial patterns of CE alterations. Longitudinal analyses assessed the subgroups’ clinical trajectories over 12 months of antipsychotic treatment. Furthermore, CE maps were integrated with transcriptomic and neuroreceptor datasets to analyse potential molecular mechanisms underlying the observed CE abnormalities.

Results

Relative to HCs, FES patients exhibited CE abnormalities primarily in the bilateral frontal lobes, sensorimotor cortex, and right cuneus. Two subtypes were identified, differing in both the spatial extent of CE abnormalities and their clinical profiles: FES1 showed more widespread CE reductions across frontal and association cortices, associated with greater affective and cognitive burden, whereas FES2 demonstrated a comparatively preserved CE profile and milder symptom expression. Subsequent transcriptomic and receptor analyses revealed distinct biological underpinnings: FES1 was associated with synaptic dysfunction and neurodevelopmental disruption, while FES2 reflected multisystem involvement potentially accompanied by compensatory processes.

Conclusions

CE-based subtyping captures clinically and biologically meaningful heterogeneity in FES. Moreover, this approach provides a promising framework for bridging neural circuit dysfunction with molecular signatures and may advance precision psychiatry in SCZ.